专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09011968B2 Alteration of graphene defects 有权
标题翻译：改变石墨烯缺陷
公开(公告)号：US09011968B2
公开(公告)日：2015-04-21
申请号：US13391158
申请日：2011-09-16
申请人： Seth Miller , Thomas Yager
发明人： Seth Miller , Thomas Yager
IPC分类号： B05D5/12 , C01B31/04 , B05C3/20 , B05C3/00 , B32B3/10 , B32B9/04
CPC分类号： C01B32/194 , B05C3/02 , B05C3/20 , B05D5/12 , B32B3/10 , B32B9/04 , C01B32/182 , C01B32/184 , Y10T428/24331
摘要： Technologies are generally described for method and systems effective to at least partially alter a defect in a layer including graphene. In some examples, the methods may include receiving the layer on a substrate where the layer includes at least some graphene and at least some defect areas in the graphene. The defect areas may reveal exposed areas of the substrate. The methods may also include reacting the substrate under sufficient reaction conditions to produce at least one cationic area in at least one of the exposed areas. The methods may further include adhering graphene oxide to the at least one cationic area to produce a graphene oxide layer. The methods may further include reducing the graphene oxide layer to produce at least one altered defect area in the layer.
摘要翻译：通常描述了有效地至少部分地改变包括石墨烯的层中的缺陷的方法和系统的技术。在一些示例中，所述方法可以包括在衬底上接收该层，其中层包括至少一些石墨烯和石墨烯中的至少一些缺陷区域。缺陷区域可能暴露基底的暴露区域。所述方法还可包括在足够的反应条件下使底物反应以在至少一个暴露区域中产生至少一个阳离子区域。所述方法还可以包括将氧化石墨烯粘附到至少一个阳离子区域以产生氧化石墨烯氧化物层。所述方法还可以包括减少石墨烯氧化物层以在该层中产生至少一个改变的缺陷区域。

2. 发明授权

US07991557B2 Computer system and methods for constructing biological classifiers and uses thereof 失效
标题翻译：用于构建生物分类器的计算机系统和方法及其用途
公开(公告)号：US07991557B2
公开(公告)日：2011-08-02
申请号：US10568264
申请日：2005-06-20
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
IPC分类号： G01N33/48
CPC分类号： G06F19/24 , G06F19/18 , Y02A90/24 , Y02A90/26
摘要： The present invention provides systems and method for constructing classifiers that distinguish between trait subgroups using molecular marker data from blood samples. The invention further encompasses the use of the classifiers and combinations of molecular markers identified by the classifiers in a wide variety of applications including: diagnosis; prognosis; prediction of disease, stage of disease or disease risk; monitoring disease progression and/or regression; monitoring disease reoccurrence and identifying risk of disease reoccurrence; determining and/or predicting response to treatment and/or treatment outcomes; monitoring and/or predicting treatment compliance or non compliance and the like. The invention further provides a variety of selected molecular markers and a means to identify combinations of the selected molecular markers useful for diagnosing particular traits of interest.
摘要翻译：本发明提供用于构建分类器的系统和方法，其使用来自血液样品的分子标记数据区分特征亚组。本发明还包括在各种应用中使用分类器和由分类器鉴定的分子标记物的组合，包括：诊断; 预后; 疾病预测，疾病阶段或疾病风险; 监测疾病进展和/或消退; 监测疾病复发并发现疾病复发的风险; 确定和/或预测对治疗和/或治疗结果的反应; 监测和/或预测治疗依从性或不合规等。本发明进一步提供了多种选择的分子标记和识别用于诊断感兴趣的特定性状的所选分子标记物的组合的方法。

3. 发明申请

US20110020809A1 MILD OSTEOARTHRITIS BIOMARKERS AND USES THEREOF 失效
标题翻译： MILD OSTEOARTHRITIS生物标记及其用途
公开(公告)号：US20110020809A1
公开(公告)日：2011-01-27
申请号：US12777140
申请日：2010-05-10
申请人： Choong-Chin Liew , Hongwei Zhang , Adam Dempsey , Thomas Yager , Samuel Chao
发明人： Choong-Chin Liew , Hongwei Zhang , Adam Dempsey , Thomas Yager , Samuel Chao
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N2800/102
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.
摘要翻译：本发明涉及新生物标志物的鉴定和选择以及与没有骨关节炎的个体相比，在具有轻度骨关节炎的个体中差异表达的新型生物标志物组合的鉴定和选择。与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质也包括在本发明的范围内，如含有用于诊断轻度骨关节炎的所述多核苷酸和蛋白质的试剂盒。本发明进一步包括使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质，以监测个体的疾病回归并监测治疗方案的功效。本发明还提供了使用本发明的生物标志物的产物鉴定骨关节炎的新型治疗靶标的方法。

4. 发明申请

US20110020808A1 BIOMARKERS FOR DIAGNOSING SCHIZOPHRENIA AND BIPOLAR DISORDER 失效
标题翻译：生物标记物用于诊断SCHIZOPHRENIA和BIPOLAR DISORDER
公开(公告)号：US20110020808A1
公开(公告)日：2011-01-27
申请号：US12777042
申请日：2010-05-10
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/158 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.
摘要翻译：本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并且可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和蛋白质。本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。本发明还提供了鉴定使用本发明的生物标志物的产物在鉴定精神分裂症和/或双相性精神障碍的新型治疗靶标的方法，以及筛选所述生物标志物的基因以获得另外的疾病标志物的方法。

5. 发明授权

US07713702B2 Biomarkers for diagnosing schizophrenia and bipolar disorder 失效
标题翻译：用于诊断精神分裂症和双相情感障碍的生物标志物
公开(公告)号：US07713702B2
公开(公告)日：2010-05-11
申请号：US12287629
申请日：2008-10-10
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
IPC分类号： C12Q1/68 , C12P19/34
CPC分类号： C12Q1/6883 , C12Q2600/158 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.
摘要翻译：本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和蛋白质。本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。本发明还提供了鉴定使用本发明的生物标志物的产物在鉴定精神分裂症和/或双相性精神障碍的新型治疗靶标的方法，以及筛选所述生物标志物的基因以获得另外的疾病标志物的方法。

6. 发明申请

US20090208942A1 Method and Apparatus for Correlating Levels of Biomarker Products with Disease 失效
标题翻译：将生物标志物产品与疾病相关联的方法和装置
公开(公告)号：US20090208942A1
公开(公告)日：2009-08-20
申请号：US12091049
申请日：2006-10-23
申请人： Choong-Chin Liew , Mark Han , Thomas Yager , Samuel Chao , Run Zheng , Hongwei Zhang
发明人： Choong-Chin Liew , Mark Han , Thomas Yager , Samuel Chao , Run Zheng , Hongwei Zhang
IPC分类号： C12Q1/68 , G06G7/48
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16 , G06F19/12 , G06F19/18 , G06F19/20 , G06F19/24 , G16H50/30 , Y02A90/26
摘要： In one aspect the invention is a method of testing for one or more colorectal pathologies or one or more subtypes of colorectal pathology (in one embodiment colorectal cancer) in a test individual by providing data corresponding to a level of products of selected biomarkers and applying the data to a formula to provide an indication of whether the test individual has one or more colorectal pathologies or one or more subtypes of colorectal pathology. In some aspects the method is computer based and a computer applies the data to the formula. In other aspects a computer system is configured with instructions that cause the processor to provide a user with the indication of whether the test individual has colorectal pathology. Also encompassed are kits for measuring data corresponding to the products of selected biomarkers which in some embodiments include a computer readable medium. Also encompassed are kits and methods of monitoring therapeutic efficacy of treatments for one or more colorectal pathologies.
摘要翻译：在一个方面，本发明是通过提供对应于所选生物标志物的产物水平的数据并应用所述生物标记物的一个或多个结直肠病理学或一种或多种结直肠病理学（在一个实施方案中为结肠直肠癌）亚型的方法，数据提供给公式，以提供测试个体是否具有一种或多种结肠直肠病变或一种或多种结直肠病理学亚型的指示。在某些方面，该方法是基于计算机的，并且计算机将数据应用于公式。在其他方面，计算机系统配置有指令，其使得处理器向用户提供测试个体是否具有结肠直肠病理学的指示。还包括用于测量与所选生物标志物的产物相对应的数据的试剂盒，其在一些实施方案中包括计算机可读介质。还包括监测一种或多种结肠直肠病变治疗效果的试剂盒和方法。

7. 发明授权

US07222059B2 Electrophoretic trace simulator 失效
标题翻译：电泳痕迹模拟器
公开(公告)号：US07222059B2
公开(公告)日：2007-05-22
申请号：US10295964
申请日：2002-11-15
申请人： Alexandre M. Izmailov , Thomas Yager
发明人： Alexandre M. Izmailov , Thomas Yager
IPC分类号： G06F17/50 , C12Q1/68
CPC分类号： G01N27/44717 , G01N27/44721
摘要： A simulated electrophoretic trace is prepared by first obtaining an input file containing an input base sequence comprising a string of letters (A, C, G and/or T) in an order corresponding to the input base sequence, and then modifying the input file using one or more functions to take into account perturbations associated with (1) changes in peak intensity as a function of base number; (2) peak shape as a function of base number; (3) peak skew; (4) spacing between peaks; (5) background; (6) noise; (7) spectral cross-talk; (8) instrumental effects and/or (9) gel electrophoresis effects to produce a modified file representing a simulated electrophoretic trace. The method may be performed using a specially adapted apparatus.
摘要翻译：通过首先以与输入的基本序列相对应的顺序获得包含字母串（A，C，G和/或T）的输入基序列的输入文件，然后使用考虑与（1）峰值强度变化作为基数的函数相关的扰动的一个或多个功能; （2）峰值形状作为基数的函数; （3）峰偏; （4）峰之间的间距; （5）背景; （6）噪音; （7）频谱串扰; （8）仪器效应和/或（9）凝胶电泳效应以产生表示模拟电泳迹线的修改文件。该方法可以使用特别适配的装置来执行。

8. 发明申请

US20050221383A1 Osteoarthritis biomarkers and uses thereof 审中-公开
标题翻译：骨关节炎生物标志物及其用途
公开(公告)号：US20050221383A1
公开(公告)日：2005-10-06
申请号：US10915680
申请日：2004-08-09
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao , Hongwei Zhang , Wayne Marshall
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao , Hongwei Zhang , Wayne Marshall
IPC分类号： C07K16/28 , C12N20060101 , C12N15/113 , C12Q1/68 , G01N33/53 , G01N33/564
CPC分类号： G01N33/564 , C12N15/113 , C12N2310/11 , C12N2310/12 , C12N2310/14 , C12N2310/15 , C12Q1/6883 , C12Q2600/158 , G01N2800/105 , G01N2800/52
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and/or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The biomarkers of the invention may be utilized to diagnose arthritis, differentiate between two stages of osteoarthritis and diagnose a particular stage of osteoarthritis. The invention provides kits comprising polynucleotides and/or proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention. Such kits are useful in diagnosing arthritis, differentiating between two stages of osteoarthritis, diagnosing a particular stage of osteoarthritis monitoring disease progression, and monitoring the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.
摘要翻译：本发明涉及新型生物标志物的鉴定和选择以及在骨关节炎和/或在骨关节炎的特定阶段中差异表达的新型生物标志物组合的鉴定和选择，以及选择新型生物标志物组合的方法。本发明的生物标志物可用于诊断关节炎，区分两个阶段的骨关节炎并诊断特定的骨关节炎阶段。本发明提供了包含与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和/或蛋白质的试剂盒。这样的试剂盒可用于诊断关节炎，区分两个阶段的骨关节炎，诊断监测疾病进展的骨关节炎的特定阶段以及监测治疗方案的功效。本发明还提供了使用本发明的生物标志物的产物鉴定骨关节炎的新型治疗靶标的方法。

9. 发明授权

US08258284B2 Kits and primers for diagnosing schizophrenia 失效
标题翻译：用于诊断精神分裂症的试剂盒和底物
公开(公告)号：US08258284B2
公开(公告)日：2012-09-04
申请号：US12777042
申请日：2010-05-10
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
IPC分类号： C07H21/04
CPC分类号： C12Q1/6883 , C12Q2600/158 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.
摘要翻译：本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和蛋白质。本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。本发明还提供了鉴定使用本发明的生物标志物的产物在鉴定精神分裂症和/或双相性精神障碍的新型治疗靶标的方法，以及筛选所述生物标志物的基因以获得另外的疾病标志物的方法。

10. 发明申请

US20090098564A1 Biomarkers for diagnosing schizophrenia and bipolar disorder 失效
标题翻译：用于诊断精神分裂症和双相情感障碍的生物标志物
公开(公告)号：US20090098564A1
公开(公告)日：2009-04-16
申请号：US12287629
申请日：2008-10-10
申请人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
发明人： Choong-Chin Liew , Thomas Yager , Adam Dempsey , Samuel Chao
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/158 , Y02A90/22 , Y02A90/24 , Y02A90/26
摘要： The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.
摘要翻译：本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并且可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内，因为包含所述多核苷酸的组合物和试剂盒和蛋白质。本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。本发明还提供了鉴定使用本发明的生物标志物的产物在鉴定精神分裂症和/或双相性精神障碍的新型治疗靶标的方法，以及筛选所述生物标志物的基因以获得另外的疾病标志物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式